
3 new blood disease drugs eligible for health insurance coverage in Korea
The Korean health insurance agency has opened the door for polycythemia vera treatment Besremi (ropeginterferon alfa-2b), third-generation Bruton's tyrosine kinase (BTK) inhibitor Jaypirca (pirtobrutinib), and multiple myeloma antibody Darzalex ( …